Abstract 3290
Background
Meningioma growth rates are highly variable, even within benign subgroups, causing some cases to remain stable while others grow rapidly despite radiotherapy. Biomarkers that differentiate meningiomas by aggression and enable prediction of their biological behavior would therefore be clinically beneficial.
Methods
Microarrays were used to identify microRNA (miRNA) expression in primary recurrent, non-recurrent and secondary meningiomas of all grades. miRNAs found to be deregulated in the microarray experiments were validated by quantitative real-time PCR using samples from a cohort of 191 patients (median age 56). Statistical analysis of the resulting dataset revealed miRNA predictors of meningioma recurrence.
Results
miRNAs exhibiting differential expression (independently of histological grade) in primary recurrent, non-recurrent and secondary meningiomas were identified. The most effective predictive model included miR-331-3p, extent of tumor resection and its localization as predictive markers. The model with a recurrence probability cut-off of 28% and small number of the input data (7) had a high area under the curve (AUC) (0.829), sensitivity (75%), specificity (75%), and acceptable leave-one-out cross-validation (LOOCV) test error (23.2%). miR-18a-5p, miR-130b-3p, miR-146a-5p, miR-1271-5p, age at diagnosis, gender and histological grade showed to be supportive but not predictive factors in the tested models.
Conclusions
This model is a novel predictor of meningioma recurrence that could facilitate optimal postoperative management. Moreover, combining this model with information on the molecular processes underpinning recurrence could enable the identification of distinct meningioma subtypes and targeted therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Health of the Czech Republic (15-29021A); Palacky University Olomouc (LF 2019_003); Ministry of Education, Youth and Sports of the Czech Republic (LO1304, LM2015091); European Regional Development Fund (ENOCH CZ.02.1.01/0.0/0.0/16_019/0000868).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract